PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1965273
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1965273
The global Wet Age-Related Macular Degeneration (wet AMD) market is witnessing steady growth driven by rising prevalence of age-related vision loss, increasing demand for advanced anti-VEGF therapeutics, and expanding healthcare infrastructure worldwide. The market is anticipated to grow from USD 3.8 billion in 2025 to USD 5.2 billion by 2032, registering a CAGR of 4.7% during 2026-2032. Growth is supported by the aging global population and increasing adoption of intravitreal injections of biologic agents that help preserve or improve vision in patients with neovascular AMD. The market's expansion is further bolstered by rising screening rates, heightened disease awareness among clinicians and patients, and broader insurance coverage across key healthcare systems.
Key Insights
Market Structure: The wet AMD market is fragmented, with competition driven by product efficacy, clinical backing, and access across geographies.
Therapeutic Dominance: Anti-VEGF agents such as aflibercept (Eylea), ranibizumab (Lucentis), and bevacizumab (Avastin) remain central to treatment strategies due to established clinical efficacy.
Regulatory & Treatment Drivers: Increasing global geriatric populations and widespread clinical acceptance of intravitreal biologics are key factors driving sustained demand for wet AMD therapeutics.
Age Segmentation: Patients above 80 years hold the largest share, reflecting the strong age-dependent incidence of wet AMD, while the 40-59 years group is the fastest-growing segment due to improved diagnostic access and treatment seeking.
Route of Administration: Intravitreal administration remains dominant, accounting for the vast majority of treatments as it delivers targeted drug efficacy directly to retinal tissues.
End User Trends: The hospitals & clinics segment holds the largest share because of specialized ophthalmology services, while homecare is the fastest-growing category driven by long-acting therapies and evolving care delivery models.
Regional Outlook: North America leads as the largest region for wet AMD care due to high disease prevalence, advanced screening programs, and robust reimbursement frameworks. Asia-Pacific is the fastest-growing region, propelled by expanding healthcare infrastructure and rising awareness.
Innovation Trends: Emergence of biosimilars and next-generation delivery systems is shaping competitive dynamics, enhancing affordability and patient access.
Healthcare Access: Expanding insurance coverage and national health initiatives are increasing treatment uptake, particularly among older patients in developed and emerging markets.